Taiki Okumura

Dr. Taiki Okumura

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
TITakanobu Iwadare
Takanobu Iwadare
TKTakefumi Kimura
Takefumi Kimura
HKHideo Kunimoto
Hideo Kunimoto
Naoki TanakaNaoki Tanaka
Naoki Tanaka
SWShun-ichi Wakabayashi
Shun-ichi Wakabayashi
TUTakeji Umemura
Takeji Umemura
Aim: Pemafibrate (PEM) is a novel selective peroxisome proliferator-activated receptor alpha modulator that is effective for hypertriglyceridemia accompanying non-alcoholic fatty liver disease (HTG-NAFLD). This study aimed to identify the predictors of PEM efficacy for HTG-NAFLD in clinical practice. Methods: We retrospectively enrolled 88 HTG-NAFLD patients treated with PEM for 6 months for the analysis of routine blood and body composition testing. A PEM response was defined as a decrease in serum alanine aminotransferase (ALT) of >30% compared with pre-treatment level. The clinical features related to PEM responsiveness were statistically tested between responders and non-responders. Results: All 88 patients completed the 6 month drug regimen without any adverse effects. PEM treatment significantly decreased liver enzymes, triglycerides, and total cholesterol levels, without any detectable impact on body weight or body composition. Comparisons of baseline clinical features revealed female and greater aspartate aminotransferase (AST), ALT, and fat mass % levels to be significantly associated with a PEM response. The optimal cut-off values to predict responders as determined by receiver operating characteristic analysis were AST 45 U/L, ALT 60 U/L, and fat mass 37%. Conclusions: Female HTG-NAFLD patients with higher transaminase and fat mass % levels may be preferentially indicated for PEM treatment. Additional large-scale prospective studies are warranted to verify our results.

9 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TOTaiki Okumura
Taiki Okumura
TKTakefumi Kimura
Takefumi Kimura
TITakanobu Iwadare
Takanobu Iwadare
SWShun-ichi Wakabayashi
Shun-ichi Wakabayashi
HKHiroyuki Kobayashi
Hiroyuki Kobayashi
TUTakeji Umemura
Takeji Umemura
Background: Serum C-reactive protein (CRP) is an established biomarker for acute inflammation and has been identified as a prognostic indicator for hepatocellular carcinoma (HCC). However, the significance of the serum CRP level, specifically in HCC patients treated with lenvatinib, remains unclear. Methods: We retrospectively analyzed 125 HCC patients who received lenvatinib treatment at six centers. Clinical characteristics were assessed to identify clinical associations between serum CRP and HCC prognosis. Results: The median overall serum CRP level was 0.29 mg/dL. The cohort was divided into two groups: the low-CRP group with a serum CRP < 0.5 mg/dL and the high-CRP group with a serum CRP ≥ 0.5 mg/dL. The low-CRP group exhibited significantly longer overall survival (OS) than the high-CRP group (22.9 vs. 7.8 months, p < 0.001). No significant difference was observed for progression-free survival (PFS) between the high- and low-CRP groups (9.8 vs. 8.4 months, p = 0.411), while time-to-treatment failure (TTF) was significantly longer in the low-CRP group (8.5 vs. 4.4 months, p = 0.007). The discontinuation rate due to poor performance status was significantly higher in the high-CRP group (p < 0.001). Conclusion: A baseline serum CRP level exceeding 0.5 mg/dL was identified as an unfavorable prognostic factor in HCC patients receiving lenvatinib treatment.

1 June 2020 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TOTaiki Okumura
Taiki Okumura
KSKeisuke Soya
Keisuke Soya
YHYu Hihara
Yu Hihara
SMShinji Muraoka
Shinji Muraoka
YNYoshihiro Nishimura
Yoshihiro Nishimura
GMGo Matsumoto
Go Matsumoto
A 48-year-old man presented with a sustained fever. Abdominal computed tomography revealed multilocular liver abscesses. He underwent percutaneous needle aspiration, yielding straw-colored pus. Gram staining revealed Gram-negative coccobacilli. The organism grew only on chocolate II agar in a 7% carbon dioxide atmosphere. Identification of Aggregatibacter aphrophilus was confirmed using mass spectrometry and 16S rRNA gene sequencing. He was successfully treated with antibiotics. Liver abscess caused by A. aphrophilus is extremely rare. We herein report the first such case in Japan. Even fastidious organisms, such as A. aphrophilus, should be correctly identified using mass spectrometry or 16S rRNA gene sequencing for adequate treatment.

17 October 2024 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
TITakanobu Iwadare
Takanobu Iwadare
TKTakefumi Kimura
Takefumi Kimura
YYYuki Yamashita
Yuki Yamashita
TOTaiki Okumura
Taiki Okumura
SWShun-ichi Wakabayashi
Shun-ichi Wakabayashi
TUTakeji Umemura
Takeji Umemura
INTRODUCTION: A straightforward, reliable, and noninvasive method for predicting the development of liver-related events (LRE) in primary biliary cholangitis (PBC) has not been attained thus far. This study investigated whether serum autotaxin (ATX) could predict LRE in patients with PBC. METHODS: This retrospective multicenter investigation included 190 biopsy-proven untreated patients with PBC. All subjects were followed for at least 1 year, during which time the prevalence of LRE, including newly developing hepatocellular carcinoma, esophagogastric varices, ascites, and hepatic encephalopathy, was investigated in relation with ATX levels at the time of liver biopsy. RESULTS: During the median follow-up period of 9.7 years, LRE were observed in 22 patients (11.6%). The area under the receiver operating characteristic curve and cutoff value of serum ATX for predicting LRE were 0.80 and 1.086 mg/L, respectively. Patients with serum ATX ≥1.086 had a significantly higher cumulative incidence of LRE compared with patients with ATX < 1.086 (33.3% vs 3.6%, P < 0.00001). Notably, the predictive capability of ATX for LRE in patients with PBC surpassed that of FIB-4, ALBI, APRI, and Mac-2-binding protein glycan isomer. A multivariate Cox proportional hazards model revealed ATX as an independent associated factor for LRE (hazard ratio 6.24, 95% confidence interval 1.87–20.80, P = 0.003) along with Nakanuma stage (hazard ratio 2.75, 95% confidence interval 1.52–4.99, P < 0.001). These results were closely replicated in a serologically diagnosed PBC validation cohort (n = 32). DISCUSSION: Serum ATX levels may serve as a predictive marker for LRE in patients with PBC.

2 June 2023 in Human Immunology
Verified
Journal Article
Closed access
TOTaiki Okumura
Taiki Okumura
SJSatoru Joshita
Satoru Joshita
TYTomoo Yamazaki
Tomoo Yamazaki
TITakanobu Iwadare
Takanobu Iwadare
SWShun-Ichi Wakabayashi
Shun-Ichi Wakabayashi
TUTakeji Umemura
Takeji Umemura

1 March 2022 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TOTaiki Okumura
Taiki Okumura
KMKenta Mitsui
Kenta Mitsui
SDSeiichi Daikuhara
Seiichi Daikuhara
TTToshiharu Tatai
Toshiharu Tatai
HIHiroko Itagaki
Hiroko Itagaki
YGYukio Gibo
Yukio Gibo
Disseminated carcinomatosis of the bone marrow (DCBM) is often accompanied by disseminated intravascular coagulation (DIC) and has a poor prognosis. DCBM develops most frequently in gastric cancer and is rarely associated with intrahepatic cholangiocarcinoma. A 41-year-old man was incidentally found to have DIC on his regular visit for ulcerative colitis and was diagnosed with DCBM with intrahepatic cholangiocarcinoma. He received intensive care, including chemotherapy, but died suddenly from hyperkalemia, possibly due to tumor lysis syndrome (TLS). The autopsy showed the periductal infiltrating type of intrahepatic cholangiocarcinoma and tumor necrosis, possibly due to chemotherapy, indicating the effectiveness of chemotherapy for DCBM with intrahepatic cholangiocarcinoma.